Clinical trial · Interventional
Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells
Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy
NCT01108380CI-TRIAL-00004198unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For patient with liver cirrhosis who need to right or extended right hepatectomy, we will treat with autologous peripheral stem cells transplantation to facilitate liver regeneration. We will asses liver regeneration by evaluation of liver volume and liver function test.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cirrhosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Plasma pheresis, Right portal vein embolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1. CD34
- description
- 1. 4 days injection of G-CSF (10μg/kg, Subcutaneous infusion) 2. On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells) 3. CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell) 4. In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed.
- interventionNames
- Procedure: Plasma pheresis, Right portal vein embolization
- type
- ACTIVE_COMPARATOR
- label
- 2. Mononucelar cell
- description
- 1. 4 days injection of G-CSF (10μg/kg, Subcutaneous infusion) 2. On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells) 3. In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed.
- interventionNames
- Procedure: Plasma pheresis, Right portal vein embolization
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with Primary hepatocellular carcinoma combined liver cirrhosis (Hepatitis B, C, Non-B Non-C) 2. Planned to right hepatectomy or extended right hepatectomy 3. Patients who need right portal vein embolization due to unsufficient expected remnant liver volume (\< 40%) or severe hepatic dysfunction (ICG R15 \> 10%) 4. Child A classification 5. ICG R15 \< 25% 6. Age: 20 - 70 years old 7. Expected life period \> 3months 8. The patients who agreed to this study Exclusion Criteria: 1. Patients who planned liver transplantation 2. Age \< 20 or \> 70 years old 3. Pregnant women 4. Patients on acute infection 5. Acute hepatic failure 6. Child class B or C 7. Heart failure 8. Existence of bleeding tendency : platelet \< 30,000, INR \> 2.2, Cr \>2.5 9. Patients who did not agree to this study
References
Publications (0)
Data not yet available
No reference posted for this study.